RT Journal Article
T1 Treatments for multi-system inflammatory syndrome in children - discharge, fever, and second-line therapies.
A1 Tagarro, Alfredo
A1 Domínguez-Rodríguez, Sara
A1 Mesa, Juan Miguel
A1 Epalza, Cristina
A1 Grasa, Carlos
A1 Iglesias-Bouzas, María Isabel
A1 Fernández-Cooke, Elisa
A1 Calvo, Cristina
A1 Villaverde, Serena
A1 Torres-Fernández, David
A1 Méndez-Echevarria, Ana
A1 Leoz, Inés
A1 Fernández-Pascual, María
A1 Saavedra-Lozano, Jesús
A1 Soto, Beatriz
A1 Aguilera-Alonso, David
A1 Rivière, Jacques G
A1 Fumadó, Victoria
A1 Martínez-Campos, Leticia
A1 Vivanco, Ana
A1 Pilar-Orive, Francisco Javier
A1 Alcalá, Pedro
A1 Ruiz, Beatriz
A1 López-Machín, Ana
A1 Oltra, Manuel
A1 Moraleda, Cinta
A1 EPICO Working Group, 
K1 COVID-19
K1 Children
K1 MIS-C
K1 SARS-CoV-2
AB Scarce evidence exists about the best treatment for multi-system inflammatory syndrome (MIS-C). We analyzed the effects of steroids, intravenous immunoglobulin (IVIG), and their combination on the probability of discharge over time, the probability of switching to second-line treatment over time, and the persistence of fever 2 days after treatment. We did a retrospective study to investigate the effect of different treatments on children with MIS-C from 1 March 2020 to 1 June 2021. We estimated the time-to-event probability using a Cox model weighted by propensity score to balance the baseline characteristics. Thirty of 132 (22.7%) patients were initially treated with steroids alone, 29/132 (21.9%) with IVIG alone, and 73/132 (55%) with IVIG plus steroids. The probability of early discharge was higher with IVIG than with IVIG plus steroids (hazard ratio [HR] 1.65, 95% CI 1.11-2.45, p = 0.013), but with a higher probability of needing second-line therapy compared to IVIG plus steroids (HR 3.05, 95% CI 1.12-8.25, p = 0.028). Patients on IVIG had a higher likelihood of persistent fever than patients on steroids (odds ratio [OR] 4.23, 95% CI 1.43-13.5, p = 0.011) or on IVIG plus steroids (OR 4.4, 95% CI 2.05-9.82, p 
YR 2022
FD 2022-10-25
LK http://hdl.handle.net/10668/20197
UL http://hdl.handle.net/10668/20197
LA en
DS RISalud
RD Aug 6, 2025